Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

References

• Saini L, Brandwein J. New treatment strategies for Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12(2):136–142.
   PubMed Web of Science ®Google Scholar
• Tekgunduz E, Goker H, Kaynar L, et al. Adult Philadelphia chromosome-positive acute lymphoblastic leukemia in daily practice: a multicenter experience. Clin Lymphoma Myeloma Leuk. 2016;16(5):269–274.
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian H, Jabbour E, et al. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2017;30(3):193–200.
   PubMed Web of Science ®Google Scholar
• Ribera JM. Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma. 2013;54(1):21–27.
   PubMed Web of Science ®Google Scholar
• Ravandi F. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011;11(2):198–203.
   PubMed Web of Science ®Google Scholar
• Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392–399.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang C, Gao L, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in southwest China. J Hematol Oncol. 2015;8:90.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Gorin NC, et al. Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Eur J Cancer. 2014;50(2):411–417.
   PubMed Web of Science ®Google Scholar
• Giebel S, Labopin M, Potter M, et al. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2018;96:73–81.
   PubMed Web of Science ®Google Scholar
• Ding Z, Han MZ, Chen SL, et al. Outcomes of adults with acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of Pretransplantation minimal residual disease:analysis from a single center of China. Chin Med J (Engl). 2015;128(15):2065–2071.
   PubMed Web of Science ®Google Scholar
• Joachim H, Deeg MD, Rainer Storb MD. Graft-versus-host disease: pathophysiological and clinical aspects. Ann Rev Med. 1984;34:11–24.
   Google Scholar
• Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215–233.
   PubMed Web of Science ®Google Scholar
• Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010;116(18):3409–3417.
   PubMed Web of Science ®Google Scholar
• Xavier Thomas MH. Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol Oncol. 2016;5(2):77–90.
   PubMedGoogle Scholar
• Malagola M, Papayannidis C, Baccarani M. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. Ann Hematol. 2016;95(5):681–693.
   PubMed Web of Science ®Google Scholar
• Ronson A, Tvito A, Rowe JM. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia. Curr Treat Options Oncol. 2017;18(3):20.
   PubMed Web of Science ®Google Scholar
• Hatta Y, Mizuta S, Matsuo K, et al. Final analysis of the JALSG Ph + ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph + ALL. Ann Hematol. 2018;97(9):1535–1545.
   PubMed Web of Science ®Google Scholar
• Fujisawa S, Mizuta S, Akiyama H, et al. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol. 2017;92(4):367–374.
   PubMed Web of Science ®Google Scholar
• Fakih R E, Jabbour E, Ravandi F, et al. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol. 2018;93(2):286–295.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125(24):3711–3719.
   PubMed Web of Science ®Google Scholar
• Kim DY JY, Lim SN, Kim SD, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126(6):746–756.
   PubMed Web of Science ®Google Scholar
• Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013;19(1):150–155.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB study 10001 (alliance). Haematologica. 2014;99(1):111–115.
   PubMed Web of Science ®Google Scholar
• Chen J, Yang L, Fan Y, et al. Comparison of autologous stem cell transplantation versus haploidentical donor stem cell transplantation for favorable- and intermediate-risk acute myeloid leukemia patients in first complete remission. Biol Blood Marrow Transplant. 2018;24(4):779–788.
   PubMed Web of Science ®Google Scholar
• Leonard JT, Stock W. The Persistence of minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia: we know it’s bad, now what? Biol Blood Marrow Transplant. 2016;22(11):1913–1914.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Imai K, Mizuta S, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 2016;51(1):43–50.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504–507.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
   PubMed Web of Science ®Google Scholar
• Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.
   PubMedGoogle Scholar
• Feng J, Gong XY, Jia YJ, et al. Spectrum of somatic mutations and their prognostic significance in adult patients with B cell acute lymphoblastic leukemia. Zhonghua xue ye xue za zhi = Zhonghua Xueyexue Zazhi. 2018;39(2):98–104.
   PubMedGoogle Scholar